Nephrogenic systemic fibrosis risk and liver disease

5Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objective. Evaluate the incidence of nephrogenic systemic fibrosis (NSF) in patients with liver disease in the peritransplant period. Materials and Methods. This IRB approved study retrospectively reviewed patients requiring transplantation for cirrhosis, hepatocellular carcinoma (HCC), or both from 2003 to 2013. Records were reviewed identifying those having gadolinium enhanced MRI within 1 year of posttransplantation to document degree of liver disease, renal disease, and evidence for NSF. Results. Gadolinium-enhanced MRI was performed on 312 of 837 patients, including 23 with severe renal failure (GFR < 30 mL/min/1.73 cm2) and 289 with GFR > 30. Two of 23 patients with renal failure developed NSF compared to zero NSF cases in 289 patients with GFR > 30 (0/289; P<0.003). High dose gadodiamide was used in the two NSF cases. There was no increased incidence of NSF with severe liver disease (1/71) compared to nonsevere liver disease (1/241; P=0.412). Conclusion. Renal disease is a risk factor for NSF, but in our small sample our evidence suggests liver disease is not an additional risk factor, especially if a low-risk gadolinium agent is used. Noting that not all patients received high-risk gadolinium, a larger study focusing on patients receiving high-risk gadolinium is needed to further evaluate NSF risk in liver disease in the peritransplant period. © 2014 Robert F. Hanna et al.

References Powered by Scopus

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

6346Citations
N/AReaders
Get full text

Management of hepatocellular carcinoma

5321Citations
N/AReaders
Get full text

Gadolinium - A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

1668Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Gadolinium-based contrast agents: A comprehensive risk assessment

300Citations
N/AReaders
Get full text

Prospective cohort study of nephrogenic systemic fibrosis in patients with stage 3-5 chronic kidney disease undergoing mri with injected gadobenate dimeglumine or gadoteridol

51Citations
N/AReaders
Get full text

Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: Results of a prospective, open-label, multicenter study

47Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Hanna, R. F., Finkelstone, L. A., Chow, D. S., Miloushev, V. Z., Escudero, M. R., Lagana, S. M., & Prince, M. R. (2014). Nephrogenic systemic fibrosis risk and liver disease. International Journal of Nephrology, 2014. https://doi.org/10.1155/2014/679605

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

60%

Researcher 2

40%

Readers' Discipline

Tooltip

Medicine and Dentistry 5

56%

Psychology 2

22%

Nursing and Health Professions 1

11%

Mathematics 1

11%

Save time finding and organizing research with Mendeley

Sign up for free